Role of the DNA damage response in prostate cancer formation, progression and treatment
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Role of the DNA damage response in prostate cancer formation, progression and treatment
Authors
Keywords
-
Journal
PROSTATE CANCER AND PROSTATIC DISEASES
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-06-13
DOI
10.1038/s41391-019-0153-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer
- (2019) Elena Castro et al. JOURNAL OF CLINICAL ONCOLOGY
- Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations
- (2019) Catherine H. Marshall et al. EUROPEAN UROLOGY
- Comprehensive molecular classification of localized prostate adenocarcinoma reveals a tumour subtype predictive of a non-aggressive disease
- (2018) A Kamoun et al. ANNALS OF ONCOLOGY
- Whole-genome and Transcriptome Sequencing of Prostate Cancer Identify New Genetic Alterations Driving Disease Progression
- (2018) Shancheng Ren et al. EUROPEAN UROLOGY
- Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology
- (2018) Philipp Nuhn et al. EUROPEAN UROLOGY
- Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide
- (2018) Emmanuel S. Antonarakis et al. EUROPEAN UROLOGY
- Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study
- (2018) Joaquin Mateo et al. EUROPEAN UROLOGY
- PARP inhibitors for homologous recombination-deficient prostate cancer
- (2018) Eric S. Christenson et al. EXPERT OPINION ON EMERGING DRUGS
- Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012
- (2018) Maha Hussain et al. JOURNAL OF CLINICAL ONCOLOGY
- Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers
- (2018) Min Yuen Teo et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial
- (2018) Noel Clarke et al. LANCET ONCOLOGY
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- BRCAness and prostate cancer: diagnostic and therapeutic considerations
- (2018) Mallika Dhawan et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency
- (2018) Zafeiris Zafeiriou et al. EUROPEAN UROLOGY
- Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects
- (2018) Pedro Isaacsson Velho et al. EUROPEAN UROLOGY
- Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer
- (2018) Alicia Latham et al. JOURNAL OF CLINICAL ONCOLOGY
- Ex vivo treatment of prostate tumor tissue recapitulates in vivo therapy response
- (2018) Wenhao Zhang et al. PROSTATE
- Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population
- (2018) Gyorgy Petrovics et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations
- (2018) Fatima Karzai et al. Journal for ImmunoTherapy of Cancer
- EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer
- (2017) Thorsten D. Poeppel et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death
- (2017) Rong Na et al. EUROPEAN UROLOGY
- Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair–deficient Prostate Cancer
- (2017) Matti Annala et al. EUROPEAN UROLOGY
- DNA Repair in Prostate Cancer: Biology and Clinical Implications
- (2017) Joaquin Mateo et al. EUROPEAN UROLOGY
- EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer
- (2017) Philip Cornford et al. EUROPEAN UROLOGY
- EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent
- (2017) Nicolas Mottet et al. EUROPEAN UROLOGY
- Genomic hallmarks of localized, non-indolent prostate cancer
- (2017) Michael Fraser et al. NATURE
- HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures
- (2017) Helen Davies et al. NATURE MEDICINE
- Synthetic lethality and cancer
- (2017) Nigel J. O'Neil et al. NATURE REVIEWS GENETICS
- Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer
- (2017) William U. Shipley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- PARP inhibitors: Synthetic lethality in the clinic
- (2017) Christopher J. Lord et al. SCIENCE
- Androgen receptor inhibitor–induced “BRCAness” and PARP inhibition are synthetically lethal for castration-resistant prostate cancer
- (2017) Likun Li et al. Science Signaling
- Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer
- (2017) Mohammad Asim et al. Nature Communications
- Androgen receptor inhibitor–induced “BRCAness” and PARP inhibition are synthetically lethal for castration-resistant prostate cancer
- (2017) Likun Li et al. Science Signaling
- Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
- (2016) M. L. Telli et al. CLINICAL CANCER RESEARCH
- PARP inhibitor combination therapy
- (2016) Amy Dréan et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- DNA mismatch repair and the DNA damage response
- (2016) Zhongdao Li et al. DNA REPAIR
- Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer
- (2016) Heather H. Cheng et al. EUROPEAN UROLOGY
- Evaluation of the radiosensitizing potency of chemotherapeutic agents in prostate cancer cells
- (2016) Colin Rae et al. INTERNATIONAL JOURNAL OF RADIATION BIOLOGY
- Preliminary evaluation of prostate-targeted radiotherapy using131I-MIP-1095 in combination with radiosensitising chemotherapeutic drugs
- (2016) Mathias Tesson et al. JOURNAL OF PHARMACY AND PHARMACOLOGY
- Prostate cancer
- (2016) Gerhardt Attard et al. LANCET
- DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic Opportunities
- (2016) M. Dhawan et al. ONCOLOGIST
- Repair Pathway Choices and Consequences at the Double-Strand Break
- (2016) Raphael Ceccaldi et al. TRENDS IN CELL BIOLOGY
- Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate
- (2016) Michael T. Schweizer et al. Oncotarget
- Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer
- (2016) Kyle C. Strickland et al. Oncotarget
- Frequent mismatch-repair defects link prostate cancer to Lynch syndrome
- (2016) Mev Dominguez-Valentin et al. BMC Urology
- Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer
- (2016) Joseph R. Evans et al. JAMA Oncology
- The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1 −/− murine model of ovarian cancer
- (2015) Jing Huang et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- DNA-PKcs-Mediated Transcriptional Regulation Drives Prostate Cancer Progression and Metastasis
- (2015) Jonathan F. Goodwin et al. CANCER CELL
- Integrative Clinical Genomics of Advanced Prostate Cancer
- (2015) Dan Robinson et al. CELL
- PARP inhibitors: A new era of targeted therapy
- (2015) Shifalika Tangutoori et al. MATURITAS
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
- (2015) Joaquin Mateo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Castration radiosensitizes prostate cancer tissue by impairing DNA double-strand break repair
- (2015) Firas L. Tarish et al. Science Translational Medicine
- CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer
- (2015) T. Higuchi et al. Cancer Immunology Research
- Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA
- (2015) Richard B. Lanman et al. PLoS One
- Functional Ex Vivo Assay to Select Homologous Recombination-Deficient Breast Tumors for PARP Inhibitor Treatment
- (2014) K. A. T. Naipal et al. CLINICAL CANCER RESEARCH
- Base excision repair: A critical player in many games
- (2014) Susan S. Wallace DNA REPAIR
- Cisplatin in cancer therapy: Molecular mechanisms of action
- (2014) Shaloam Dasari et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study
- (2014) Elizabeth K. Bancroft et al. EUROPEAN UROLOGY
- High prevalence of mismatch repair deficiency in prostate cancers diagnosed in mismatch repair gene mutation carriers from the colon cancer family registry
- (2014) Christophe Rosty et al. Familial Cancer
- Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer
- (2014) Maha Hussain et al. INVESTIGATIONAL NEW DRUGS
- Transcription and Recombination: When RNA Meets DNA
- (2014) A. Aguilera et al. Cold Spring Harbor Perspectives in Biology
- Recombination and Replication
- (2014) A. H. Syeda et al. Cold Spring Harbor Perspectives in Biology
- BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study
- (2013) J L Lesnock et al. BRITISH JOURNAL OF CANCER
- Punctuated Evolution of Prostate Cancer Genomes
- (2013) Sylvan C. Baca et al. CELL
- Castration Therapy Results in Decreased Ku70 Levels in Prostate Cancer
- (2013) F. L. T. Al-Ubaidi et al. CLINICAL CANCER RESEARCH
- BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency
- (2013) Y. Shen et al. CLINICAL CANCER RESEARCH
- GermlineBRCAMutations Are Associated With Higher Risk of Nodal Involvement, Distant Metastasis, and Poor Survival Outcomes in Prostate Cancer
- (2013) Elena Castro et al. JOURNAL OF CLINICAL ONCOLOGY
- Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
- (2013) J. Murai et al. MOLECULAR CANCER THERAPEUTICS
- A Molecular Signature Predictive of Indolent Prostate Cancer
- (2013) S. Irshad et al. Science Translational Medicine
- Postreplicative Mismatch Repair
- (2013) J. Jiricny Cold Spring Harbor Perspectives in Biology
- A Hormone-DNA Repair Circuit Governs the Response to Genotoxic Insult
- (2013) J. F. Goodwin et al. Cancer Discovery
- Androgen Receptor Signaling Regulates DNA Repair in Prostate Cancers
- (2013) W. R. Polkinghorn et al. Cancer Discovery
- An inherited NBN mutation is associated with poor prognosis prostate cancer
- (2012) C Cybulski et al. BRITISH JOURNAL OF CANCER
- Germline BRCA1 mutations increase prostate cancer risk
- (2012) D Leongamornlert et al. BRITISH JOURNAL OF CANCER
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
- (2012) J. Murai et al. CANCER RESEARCH
- The mutational landscape of lethal castration-resistant prostate cancer
- (2012) Catherine S. Grasso et al. NATURE
- Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer
- (2012) Christopher E Barbieri et al. NATURE GENETICS
- Dual Roles of PARP-1 Promote Cancer Growth and Progression
- (2012) M. J. Schiewer et al. Cancer Discovery
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- Defining and predicting indolent and low risk prostate cancer
- (2011) Chris H. Bangma et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial
- (2011) Padraig Warde et al. LANCET
- Response of Human Prostate Cancer Cells and Tumors to Combining PARP Inhibition with Ionizing Radiation
- (2011) J. C. Barreto-Andrade et al. MOLECULAR CANCER THERAPEUTICS
- "Contextual" Synthetic Lethality and/or Loss of Heterozygosity: Tumor Hypoxia and Modification of DNA Repair
- (2010) N. Chan et al. CLINICAL CANCER RESEARCH
- Tumor Growth Inhibition by Olaparib in BRCA2 Germline-Mutated Patient-Derived Ovarian Cancer Tissue Xenografts
- (2010) U. Kortmann et al. CLINICAL CANCER RESEARCH
- Germline BRCA Mutations Denote a Clinicopathologic Subset of Prostate Cancer
- (2010) D. J. Gallagher et al. CLINICAL CANCER RESEARCH
- The DNA Damage Response: Making It Safe to Play with Knives
- (2010) Alberto Ciccia et al. MOLECULAR CELL
- Immune Checkpoint Proteins: A New Therapeutic Paradigm for Cancer—Preclinical Background: CTLA-4 and PD-1 Blockade
- (2010) Jeffrey Weber SEMINARS IN ONCOLOGY
- Brca2 and Trp53 Deficiency Cooperate in the Progression of Mouse Prostate Tumourigenesis
- (2010) Jeffrey C. Francis et al. PLoS Genetics
- How the Fanconi Anemia Pathway Guards the Genome
- (2009) George-Lucian Moldovan et al. Annual Review of Genetics
- A recurrent truncating germline mutation in the BRIP1/FANCJ gene and susceptibility to prostate cancer
- (2009) Z Kote-Jarai et al. BRITISH JOURNAL OF CANCER
- Germ-Line Mutations in Mismatch Repair Genes Associated with Prostate Cancer
- (2009) E. M. Grindedal et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Poly(ADP-Ribose) Polymerase-1 Inhibitor Treatment Regresses Autochthonous Brca2/p53-Mutant Mammary Tumors In vivo and Delays Tumor Relapse in Combination with Carboplatin
- (2009) T. Hay et al. CANCER RESEARCH
- The DNA-damage response in human biology and disease
- (2009) Stephen P. Jackson et al. NATURE
- Duration of Androgen Suppression in the Treatment of Prostate Cancer
- (2009) Michel Bolla et al. NEW ENGLAND JOURNAL OF MEDICINE
- DNA Damage, Aging, and Cancer
- (2009) Jan H.J. Hoeijmakers NEW ENGLAND JOURNAL OF MEDICINE
- Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial
- (2008) Anders Widmark et al. LANCET
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started